Results 191 to 200 of about 39,694 (240)

99mTc-centered one-pot synthesis for preparation of 99mTc radiotracers

Dalton Transactions, 2011
Nuclear medicine relies on two main imaging modalities: single photon emission computed tomography (SPECT) and positron emission tomography (PET). Radiopharmaceuticals (or radiotracers) are the blood stream of nuclear medicine for the diagnosis or therapy of diseases.
Shuang, Liu, Sudipta, Chakraborty
openaire   +2 more sources

99mTc-Aprotinin: Comparison with 99mTc-DMSA in Normal and Diseased Kidneys

Nuklearmedizin, 1984
SummaryAprotinin (A) and DMSA labelled with 99mTc were compared in patients with normal (NK, n = 12) and diseased kidneys (CRF, n = 13) by means of quantitative serial scans and measurements of blood clearance and urinary excretion. Serial scans only were obtained in additional 13 patients.
C, Aprile, R, Saponaro, G, Villa, F, Lunghi   +3 more
openaire   +2 more sources

The stability of 99mTc-DTPA and 99mTc-HIDA following ultrasonic nebulisation

European Journal of Nuclear Medicine, 1988
The stability of 99mTc-DTPA (diethylenetriamine-pentaacetic acid) and 99mTc-HIDA (2,6-diethylacetanilido-iminodiacetic acid) were evaluated following ultrasonic nebulisation. The results confirm that either of these radiopharmaceuticals can be used in our nebuliser without significant radiochemical breakdown.
N, Durovic, M, Pillay, P H, Cox
openaire   +2 more sources

Clinical experience with 99mTc-MAG3, mercaptoacetyltriglycine, and a comparison with 99mTc-DTPA

European Journal of Nuclear Medicine, 1988
The preparation, application and clinical usage of 99mTc-mercaptoacetyltriglycine, MAG3, a tubular secreted compound, is described in the first 225 patients in a phase III study. Image quality, relative renal function, and renal transit times were compared with a 4 fold greater administered activity of 99mTc-DTPA in 11 patients.
Adil A. Al-Nahhas, Rafaqat A. Jafri, Keith E. Britton, Kishor Solanki, Jamshed Bomanji, Steve Mather, Melvyn A. Carroll, Mazin Al-Janabi, Vicenzo Frusciante, Boris Ajdinowic, Francesco Fiore, Solomon Demena, Cyril C. Nimmon   +12 more
openaire   +2 more sources

99mTc ECD and 99mTc TRODAT-1 SPECT in Hashimoto Encephalopathy

Clinical Nuclear Medicine, 2012
Hashimoto encephalopathy is characterized by cognitive impairment and other neurologic symptoms, including seizure, myoclonus, tremor, ataxia, parkinsonism, and psychiatric disorders. The presence of serum antithyroglobulin antibody and/or antimicrosomal antibody is always found, and the response to steroid treatment is usually promising.
Chih-Shan, Hsu, Yu-Chin, Wu, Ming-Kuei, Lu, Yi-Ting, Hsu, Thomas Shang-Ming, Chiou, Chon-Haw, Tsai, Jui-Cheng, Chen   +6 more
openaire   +2 more sources

99mTc Colloid and 99mTc IDA Imagings in Diffuse Hepatic Disease

Journal of Clinical Gastroenterology, 1993
Ninety-six patients with various diffuse hepatic diseases were observed using both 99mTc colloid and 99mTc iminodiacetic acid (IDA), focusing on the potential etiologies of the disease process as well as its chronicity and severity. The presence of acute hepatic disease was more sensitively depicted with 99mTc IDA than with 99mTc colloid.
T, Aburano, K, Yokoyama, N, Shuke, T, Takayama, T, Michigishi, N, Tonami, K, Hisada, M, Unoura, K, Kobayashi   +8 more
openaire   +2 more sources

Physico-chemical study of the radiopharmaceuticals 99mTc-DMSA, 99mTc-EDTA and 99mTc-DTPA interaction with plasmatic proteins

International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1989
This report studies the binding rate of the radiopharmaceuticals 99mTc-DTPA, 99mTc-EDTA and 99mTc-DMSA to plasmatic proteins. The proteins bind to the tested radiopharmaceuticals in the following sequence: 99mTc-DTPA less than 99mTc-DMSA(C1) less than 99mTc-EDTA less than 99mTc-DMSA(C2) where C1 and C2 represent two different Tc-DMSA complexes.
R, Garcia Domenech, O, Abril Mendez, J, Galvez Alvarez, A, Farga Marti   +3 more
openaire   +2 more sources

The new 99mTc myocardial perfusion imaging agents: 99mTc-sestamibi and 99mTc-teboroxime.

Circulation, 1991
The two new 99m (99mTc) labeled myocardial perfusion agents, 99mTc-Sestamibi and 99mTc-Teboroxime, are now available for routine clinical application. Both agents allow assessment of ejection fraction by the first-pass technique at rest or during exercise, thus providing additional information not available with thallium-201.
D S, Berman, H, Kiat, J, Maddahi
openaire   +1 more source

Biokinetics of Bone Tracers by Means of Deconvolution Analysis - Comparison of 99mTc MDP, 99mTc DPD and 99mTc EHDP

Nuklearmedizin, 1982
Transfer functions of 99mTc methylene diphosphonate (MDP), 99mTc 2,3-dicarboxypropane-l,l-diphosphonate (DPD) and 99mTc ethane-l-hydroxy-l,l-diphosphonate (EHDP) into bone and extravascular fluid of soft tissues were determined in 5 dogs by deconvolution analysis of the time-course of plasma, soft tissue and bone radioactivity. The transfer rates 5 min
J, Knop, P, Stritzke, E, Kröger, C, Schneider, G, Wasmus   +4 more
openaire   +2 more sources

A comparison between the diagnostic efficacy of 99mTc-MDP, 99mTc-DPD and 99mTc-HDP for the detection of bone metastases

European Journal of Nuclear Medicine, 1983
We have investigated the clinical efficacy for the detection of bone metastases of two recently marketed bone-seeking radiopharmaceuticals, HDP and DPD, compared with traditionally used MDP. Twenty patients received 15 mCi 99mTc-MDP; after assessment ten of these patients later received 15 mCi 99mTc-DPD and ten other patients of this group were ...
E K, Pauwels, J, Blom, J A, Camps, J, Hermans, A M, Rijke   +4 more
openaire   +2 more sources